Omega-3 polyunsaturated fatty acid supplementation and non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials
Yan JH, Guan BJ, Gao HY, Peng XE
Medicine · 90 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- National Natural Science Foundation of China
- Subvenciones
- National Natural Science Foundation of China (81473047)
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2018-09-01 · Medicine (Baltimore) · vol. 97 · número 37 · pág. e12271
- Editorial
- Wolters Kluwer
- Citado
- 137 citas · más que el 99% de estudios similares · 9.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 48 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY-NC
- Áreas de investigación
- Liver Disease Diagnosis and Treatment · Fatty Acid Research and Health · Liver Disease and Transplantation
- Palabras clave
- Medicine, Polyunsaturated fatty acid, Cochrane Library, Meta-analysis, Internal medicine, Nonalcoholic fatty liver disease, Fatty liver, Randomized controlled trial, Gastroenterology, Insulin resistance, Publication bias, Adverse effect, Fatty acid, Disease, Insulin, Biochemistry, Biology
- MeSH
- humans, insulin resistance, blood glucose, fatty acids, omega-3, triglycerides, liver function tests, body weights and measures, dietary supplements, randomized controlled trials as topic, non-alcoholic fatty liver disease
4 autores
- Jianhui Yan🇨🇳Fujian Medical University; Fujian Provincial Cancer Hospital
- Bingjie Guan🇨🇳Fujian Medical University
- Haiyan Gao🇨🇳Fujian Medical University
- Xian‐E Peng🇨🇳 · autor de correspondenciaFujian Medical University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Clinical trials examining the therapeutic benefit of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) on nonalcoholic fatty liver disease (NAFLD) have reported inconsistent results. We performed a meta-analysis of randomized controlled trials (RCTs) examining the effect of ω-3 PUFA supplementation on NAFLD, and provide substantial evidence on whether ω-3 PUFA supplementation has a favorable effect for treating NAFLD.
Methods
We searched the PubMed, Cochrane Library, Springer Link, China National Knowledge Infrastructure (CNKI), Wanfang, and Chinese Scientific and Technological Journal (VIP) databases for RCTs on oral ω-3 PUFA supplementation in patients with NAFLD. The data were pooled; meta-analyses were conducted using random-effect or fixed-effect models.
Results
Eighteen studies involving 1424 patients were included. We found a significant benefit for ω-3 PUFAs vs control for liver fat, alanine aminotransferase, aspartate aminotransferase, γ-glutamyl transferase, triglycerides, insulin resistance, and glucose. However, there was significant interstudy heterogeneity. Subgroup and regression analyses showed no significantly clear methodologic discrepancy. Publication bias and serious adverse events were not detected.
Conclusions
Our meta-analysis suggests that ω-3 PUFA supplementation may decrease liver fat and hepatic enzyme parameters. However, more large-scale, well-designed RCTs are needed to confirm the effect of ω-3 PUFA supplementation on these parameters.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.